The Zelrix transdermal patch has recently receieved positive results from its Phase III clinical trial that ought to see this migraine patch of sorts move closer towards being manufactured for the masses. Zelrix will rely on its proprietary iontophoretic transdermal technology known as SmartRelief, where it is able to deliver sumatriptan continuously. Dubbed as “a thin, disposable, single-use device in a self-contained system,” Zelrix aims to offer migraine sufferers yet another way to alleviate their suffering just in case nothing else on the market works for them at the moment. From nicotine patches to migraine patches – what next, alcohol patches?
Next Story: Japan Texture Special Edition announced